Share
))
HBO and The Ringer's Bill Simmons hosts the most downloaded sports podcast of all time, with a rotating crew of celebrities, athletes, and media staples, as well as mainstays like Cousin Sal, Joe House, and a slew of other friends and family members who always happen to be suspiciously available.
…
continue reading
Manage episode 502638142 series 3685050
Content provided by Demy-Colton. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Demy-Colton or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Fundraising has long been a challenge for European biopharma companies, particularly those moving programs into the clinic, due to the limitations of European public markets. But change may be on the horizon.
With the rise of virtual fundraising, European innovators are finding new opportunities to access ex-EU public and private capital. But is this trend sustainable? Where does non-dilutive funding fit? Is a NASDAQ listing the right path? And what other tools should CEOs and their teams be considering as they advance their assets? In this episode, industry leaders unpack these critical questions and explore the evolving landscape of European biopharma fundraising.
24 episodes
